











VENABLE | Fitzpatrick



Technology: Rituximab is a chimeric murine/human monoclonal antibody that is directed against the CD20 antigen. CD20 is a protein that is primarily found on the surface of immune system B cells. CD20 is involved in cell growth and differentiation.

	Genentech v. Celltrion 1:18-cv- 11553 (D.N.J.) Settled Cont'd below	Genentech v. Celltrion 1:18-cv- 00574 (D.N.J.) Settled Cont'd below	Celltrion v. Genentech 4:18-cv-00276 (N.D. Cal.) Dismissed; Appeal No. 18- 2161 Dismissed Cont'd below	Genentech v. Sandoz 1:17-cv-13507 (D.N.J.) Dismissed Cont'd below	<i>Celltrion v. Genentech</i> IPR2017-01227 Institution denied	Celltrion v. Genentech IPR2017-01230 Institution denied	<i>Pfizer v.</i> <i>Genentech</i> IPR2017- 02126 Institution denied	Boehringer Ingelheim v. Genentech IPR2015-00415 Petitioner request for adverse judgment after institution	Celltrion v. Genentech IPR2015- 01744 Petitioner dismissed prior to institution decision	Celltrion v. Genentech IPR2016-01614 FWD (no instituted claim unpatentable); Appeal 18-1924 dismissed	Pfizer v. Genentech IPR2017-01115 (Joined with IPR2016-01614) FWD (no instituted claim unpatentable); Appeal 18-1885 dismissed (settled)
6,121,428		х		х							
6,242,177		х									
6,331,415	х	х	х	х							
6,417,335		х	х								
6,455,043		х	х								
6,489,447	х	х	х	х							
6,586,206		x	х								
6,610,516	х	х	х	х							
6,620,918	x	х	х	х							
6,716,602		х	х								
6,870,034				х							
7,381,560	х	х		х							
7,390,660		х	х								
7,485,704	х	х	х	х							
7,682,612		х	х		х	х	x				
7,807,799	х	х	х	х							
7,820,161	х	х	х	х				х	х	х	х
7,923,221	x	x	x	x	Boehringer Ingelheim v. Genentech IPR2015-00417 Petitioner request for adverse judgment after institution	Celltrion v. Genentech IPR2015-01733 Petitioner dismissed prior to institution decision	Celltrion v. Genentech IPR2016- 01667 Institution denied	Pfizer v. Genentech IPR2017-01923 Settled after institution	Sandoz v. Genentech IPR2017- 02036 Institution denied	Sandoz v. Genentech IPR2017-02042 Institution denied	Celltrion v. Genentech IPR2018-01019 Joined with IPR2017-01923; Settled after institution
7,976,838	x	x	х	x	х	х	х	х	х	х	х



	Genentech v. Celltrion 1:18-cv-11553 (D.N.J.) Settled Cont'd from above	Genentech v. Celltrion 1:18-cv- 00574 (D.N.J.) Settled Cont'd from above	Celltrion v. Genentech 4:18-cv-00276 (N.D. Cal.) Dismissed; Appeal No. 18-2161 Dismissed Cont'd from above	Genentech v. Sandoz 2:17-cv-13507 (D.N.J.) Dismissed Cont'd from above	Celltrion v. Genentech IPR2017- 01229 Institution denied	Pfizer v. Biogen IPR2017- 02127 Institution denied	Boehringer Ingelheim v. Biogen IPR2015- 00418 Institution denied	Celltrion v. Biogen IPR2017-01093 Institution denied	<i>Pfizer v. Biogen</i> IPR2017-01166 Institution denied; Request for rehearing withdrawn	<i>Pfizer v. Biogen</i> IPR2018-00285 Settled after institution	
8,044,017		х	Х								
8,206,711	х	х	Х	х	х	х					
8,314,225				х							
8,329,172	x	х	х	х			х	х	х	x	
8,357,301		x	x					Pfizer v. Biogen			
8,460,895		x	х		Pfizer v.	Celltrion v.	Pfizer v.	IPR2017-01168 FWD (All	Celltrion v. Biogen IPR2017-01095	Pfizer v. Biogen	Pfizer v. Biogen
8,512,983		x	x	x	Genentech IPR2018- 00086 Institution denied	Biogen IPR2017- 01094 Institution denied	Biogen IPR2017- 01167 Institution denied	instituted claims unpatentable); Appeal 19-1364 affirmed with US, settled with Pfizer	FWD (All instituted claims unpatentable); Appeal 19-1253 dismissed as to US, settled with Celltrion	IPR2018- 00186 Terminated after institution	IPR2018-00231 Petitioner dismissed prior to institution decision
8,545,843	х	х	х	х	х						
8,557,244	х	х	х	х		х	х				
8,574,869	х	х	х	х							
8,633,302		x	х								
8,710,196		х	х	х							
8,771,988		х	х								
8,821,873	x	x	х	х				х			
8,822,655		х	х								
9,047,438		х	х								
9,080,183		x	х								
9,296,821	x	x	х	x					х	x	
9,428,548		x	х								
9,428,766		х	х								
9,487,809		х	x								
9,504,744	x	х	х	х							х
9,714,293		Х	х	x							